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Introduction
Early in this century several authors suggested that vitamin C intake may have
beneficial effects on the incidence and severity of various infections. Two
exhaustive bibliographical searches of the old literature on vitamin C and infec-
tions have been published. One of them was overenthusiastic [1] in its interpre-
tation of the findings, whereas the other was overly pessimistic [2]; neither
offered any statistical analysis of the available data. However, a quantitative
analysis of controlled studies has been published recently [3]. The mechanisms
whereby vitamin C affects the immune system are poorly understood, although
there are reports indicating that it affects the functions of phagocytes, the pro-
liferation of T lymphocytes, the production of interferon, and the replication of
viruses [3-5].
Infections in Animals
Most mammals synthesize vitamin C in their liver [6]. The guinea pig is one of
the rare species that has lost this capability and thus provides a good experi-
mental model for studies examining its effects. Vitamin C intake affects the sus-
ceptibility of guinea pigs to infections by bacteria and other microorganisms
[3,7-31].
Primates also lack the ability to synthesize vitamin C [6]. Albert Sabin found
that many rhesus monkeys on a vitamin C-deficient diet succumbed to sponta-
neous infections, chiefly pneumonia and enterocolitis, while those administered
vitamin C remained well [32]. In marmosets, vitamin C supplementation
decreased morbidity and mortality due to parainfluenza infection [33].
Mice, rats, and rabbits synthesize vitamin C in their livers and thus cannot
be used to study the effects of vitamin C deficiency, but the effects of supple-
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mentation can be studied in these species. Vitamin C decreased the morbidity
and mortality of animals infected with several different kinds of microorgan-
isms [3, 34-38]. Furthermore, it has been commented that humans, monkeys,
and the guinea pig are susceptible to both the human and bovine tubercle bacil-




The effect of vitamin C on the common cold has been extensively studied, pri-
marily because of the wide publicity provoked in the early 1970s by Linus
Pauling [40, 41]. Pauling did not carry out any experimental work himself, but
based his conclusions on published data. So far, over 60 interventional studies
examining this issue have been published [42], The effect of vitamin C on the
common cold has been a controversial issue largely because of conflicting
results. Nevertheless, important consistencies in the results can be seen on care-
ful analysis.
Incidence of the Common Cold
There is strong evidence that large-dose vitamin C supplementation has no
effect on the number of common cold episodes in ordinary people in Western
countries. None of the six largest trials found any significant effect, and when
their results were combined, no difference was seen between vitamin C and
placebo groups [43], In these trials there were over 3500 subjects and over 5000
common cold episodes in all.
Nevertheless, a number of small-scale trials have found a significantly lower
number of colds in a group supplemented with vitamin C and it is possible that
some of these positive results are explained by the use of different kinds of sub-
jects or by other differences in experimental conditions when compared to the
six largest trials.
It was suggested that subjects under acute heavy physical stress forms one
group in which vitamin C supplementation may be beneficial. In three placebo-
controlled trials, the number of cold episodes was decreased on average by 50%
in the vitamin C groups [44]. In a fourth study, vitamin C also decreased com-
mon cold incidence significantly but the control group was not administered a
placebo [45].
Furthermore, it is possible that some of the positive results on cold inci-
dence are not due to the high vitamin C dose per se, but rather to the correction
of marginal deficiency. In the UK, the dietary vitamin C intake is particularly
low among the Western countries, and in four trials in British men vitamin C
decreased the incidence of the common cold on average by 30% [43]. One of the
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UK trials used a low vitamin C dose, 80 mg/day, implying that the benefit was
due to correcting marginal deficiency [43,46],
Some further studies have also observed preventive benefits from vitamin C
on common cold incidence [40, 41, 47]. Nevertheless, the six largest trials show
that subpopulations in Western countries potentially benefiting from regular
vitamin C supplementation are rather restricted [43],
Severity of Common Cold Episodes
Placebo-controlled trials have shown that vitamin C alleviates the symptoms
and shortens the duration of the common cold. However, there has been great
divergence in the results, some studies reporting only a 5% decrease, while a
few have reported an up to 50% decrease in the duration or severity of colds
among the vitamin C group [47-51].
There is some evidence of variation in the size of the benefit between sub-
groups. Vitamin C may be more beneficial in subjects with a low dietary intake
of the vitamin and in adults in regular contact with children [3]. Studies in chil-
dren also tend to reveal greater benefit than studies in adults and studies using
larger doses tend to reveal greater benefit [51]. Karlowski et al. [52] found that 6
g/day produced approximately twice as great a benefit as 3 g/day, implying dose
dependency in the >1 g/day region [51,53].
Essentially all published trials have examined the effect of regular vitamin C
supplementation. However, if the goal is to alleviate the symptoms of cold
episodes, it appears more rational to administer vitamin C therapeutically,
starting immediately after the first symptoms, but few such trials have been car-
ried out [48, 51]. Promptness may be important in such therapeutic supplemen-
tation. Asfora [54] found great benefit from vitamin C (6 g/day for 5 days) when
treatment was initiated within 24 h of the onset of common cold symptoms.
The benefit was considerably less when initiated 24-48 h after onset, and no
benefit was seen with still later initiation of treatment.
Pneumonia
In one of his last texts Albert Szent-Györgyi mentions a personal experience
[55]: "Last year I collected a rather unfortunate personal experience. I broke
down with pneumonia which I could not shake off for months, until I discov-
ered that the quantities of ascorbic acid which I took (one gram daily) had
become insufficient at my age (84 years). When I went up from one gram to
eight, my troubles were over."
There are numerous other suggestions that vitamin C may have therapeutic
benefits in pneumonia patients [56-65]. However, we are aware of only one ran-
domized trial pertinent to this issue [66], carried out in the UK with elderly hos-
pital patients with pneumonia (n= 17) and acute bronchitis (n= 40). Therapeutic
vitamin C (0.2 g/day) caused a statistically significant decrease in a score of respi-
ratory symptoms in those patients who were most severely ill when admitted to
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hospital, and a decrease bordering on statistical significance in all patients.
Furthermore, there were six deaths among the patients, all due to respiratory
infection; five in the placebo group, but only one in the vitamin C group [66].
Vitamin C intake can also have preventive effects on pneumonia. Three
studies have reported the number of pneumonia cases in vitamin C and control
groups [67-69], each of these studies finding at least an 80% lower incidence of
pneumonia in the vitamin C group and the difference being statistically signifi-
cant in each case [70]. The latest of these studies was a double-blind, placebo-
controlled trial with marine recruits in the USA [69]. In contrast, placebo was
not used in the two older studies [67, 68]. Dietary vitamin C intake was low in
the older studies [67, 68] and the benefit of higher vitamin C intake may be
explained by the correction of marginal deficiency. However, in the latest trial
[69] dietary intake was rather high, and the effect thus seems to be due to the
large dose per se (2 g/day). In this respect, these studies do not yield a simple
biological explanation of the observed benefits.
Other Infections
There is limited and fragmentary data on the possible effects of vitamin C on
other infections, yet the available data strongly suggest that the effects are not
restricted to the common cold and pneumonia [1-39, 71]. Findings of three par-
ticularly interesting trials are shown in Table 1.
Glazebrook and Thomson [67] studied schoolboys in an institution in the
UK. A placebo was not used, but vitamin C was added to food in the kitchen
and it is unlikely that a placebo effect would have occurred in the dining hall.
No difference was seen in tonsillitis incidence between the study groups.
However, prominent differences between the control and vitamin C groups were
seen among the subjects who contracted tonsillitis. In the vitamin group fewer
tonsillitis patients were referred to hospital and their average stay at the hospi-
tal was shorter (Table 1). A further interesting finding in this trial was the
absence of pneumonia and rheumatic fever in the vitamin group. This trial
shows that vitamin C may have quite variable effects on different infectious dis-
ease endpoints. It is similarly noteworthy that Pitt and Costrini [69] found no
effect on common cold incidence but an 85% decrease in pneumonia incidence
in the vitamin C group [43, 70]. Glazebrook and Thomson estimated that the
dietary vitamin C intake of schoolboys was only 10-15 mg/day [67]. It is thus
possible that the observed benefits are due to the correction of marginal defi-
ciency. Consequently, even if we assume that their results reflect genuine bio-
logical effects, great care must be exercised when extrapolating such findings to
other population groups.
Ritzel [72, 73] carried out a double-blind, placebo-controlled trial with
schoolchildren in a skiing camp in Switzerland, which belongs to the group of
studies with subjects under acute heavy physical stress [44]. He observed a sub-
stantial decrease in the number of pharyngitis, laryngitis, and tonsillitis
episodes, and in the number of bronchitis episodes in the vitamin C group
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(Table 1). The trial was small and these decreases were not significant statisti-
cally, but they are consistent with the observed effect on common cold inci-
dence. A substantial difference between the groups in the occurrence of other
symptoms was also reported (Table 1).
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Terezhalmy et al. [74] carried out a double-blind, placebo-controlled trial
with subjects with recurrent herpes labialis. The duration of pain and the per-
centage of subjects with vesicle formation were both significantly reduced by
vitamin C (Table 1). No meaningful difference was seen between 0.6 and 1.0
g/day doses, suggesting that saturation was reached at 0.6 g/day or lower. A fur-
ther interesting finding in this trial was that prompt initiation of treatment
within 24 h was more beneficial than later initiation [3, 74], consistent with
Asfora's findings with the common cold [54]. Bioflavonoids were given along
with vitamin C and it is unknown to what extent they are responsible for the
differences between the study groups.
A number of authors have suggested that vitamin C may be beneficial in
patients with tuberculosis [1, 3, 75-84] and for preventing and treating viral
hepatitis [1, 3, 64, 65, 71, 85-91], With all the evidence indicating that vitamin C
has nonspecific effects on the immune system and on various infections [3-39],
it seems clear that these old reports should not be disregarded without further
carefully designed trials. Vitamin C has been suggested as having beneficial
effects on still further infections, but they are not commented on here [1-3, 7,
64,65,92-98].
Problems in Interpreting the Vitamin C Studies
Szent-Gyorgyi stated that "as to ascorbic acid, right from the beginning I felt
that the medical profession misled the public. If you don't take ascorbic acid
with your food you get scurvy, so the medical profession said that if you don't
get scurvy you are all right. I think that this is a very grave error. Scurvy is not
the first sign of the deficiency but a premortal syndrome, and for full health
you need much more [71,99]."
This oversimplified view vividly described by Szent-Györgyi in separate
instances [1, 100-103] is still prevalent. It recently was shown that three highly
influential reviews [104-106] concluding that vitamin C is not efficacious
against the common cold misrepresented data from the original publications
and analyzed the data improperly [107, 108]. Furthermore, the authors of the
most influential common cold trial, which was carried out at the National
Institutes of Health in the USA [52], concluded that the apparent benefit from
vitamin C was actually caused by the placebo effect. However, the placebo effect
was recently shown to be an erroneous explanation of these findings [53]. It is
noteworthy that two of these biased papers [52, 104, 109] were authored by
Thomas Chalmers who was a highly influential pioneer of randomized trials
[110]. It seems that the biased analysis of data in the four important papers [52,
104-106] is largely explained by uncritical adherence to the concept that the
physiological purpose of vitamin C is merely to prevent scurvy [3,108, 111].
There are many more problems in interpreting the vitamin C studies [3,
108]. A particular difficulty arises from the fundamental difference between vit-
amin C and ordinary drugs such as antibiotics. It is possible to select a control
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group which has no intake of an ordinary drug, making the interpretation of
results reasonably simple. It is impossible, however, to select control subjects who
have no vitamin C intake and no vitamin C in their body. Consequently, all inter-
vention studies with vitamin C compare two different intake levels. The lower
level arising from diet has not usually been estimated at all, making the compari-
son between studies and the generalization of findings problematic issues.
One important problem that has hampered acceptance of the notion that
vitamin C supplementation can produce benefits is concern for safety. For
example, in a recent review Victor Herbert [112] stated that vitamin C may
lower plasma vitamin 612 levels and reduce insulin production. However, specu-
lation that vitamin C breaks down vitamin 612 was shown to be false over two
decades ago [71, 113-115], and speculation that vitamin C reduces insulin pro-
duction was based on a single study from the year 1946 with alloxan treated
rats; however, the original authors explicitly stated that vitamin C alone had no
effect on their rats [115]. The safety of vitamin C is of no real concern [65, 71,
100,115-117]. In his reminiscences Pauling [118] recalled that the reason he sat
down and wrote the bestselling book reviewing the evidence that vitamin C is
beneficial against the common cold [40] was an acrimonious exchange of letters
with Herbert who authored the biased review claiming that vitamin C is harm-
ful [112,115].
Some people such as Szent-Györgyi [1, 55, 99-103], Pauling [40, 41, 71, 99],
and Stone [ 1 ] were able to see that the physiological role of vitamin C is not
limited to the prevention of scurvy. Nevertheless, they were overly enthusiastic
when extrapolating the reported benefits of higher doses to the general popula-
tion in Western countries [3,43,47, 51]. For example, they did not properly con-
sider the possibility that the reported benefits of high doses were due to the
correction of marginal deficiency, in which case their conclusions from the
published findings would probably have been more moderate.
The Need for Further Trials
Paul Knipschild [119] describes how a colleague once asked him to help set up a
preventive trial on vitamin C and the common cold. However, before undertak-
ing a new trial he decided first to carry out a systematic review of the issue to
see what was previously known and this led to a thorough and useful bibliogra-
phy on the subject [42].
Judging by published reports, many other workers did not take a proper
look at the literature to formulate relevant questions for their own trials.
Consequently, many published trials teach us little, if anything. For example, in
1975 it was reported that 6 g/day of vitamin C caused twice as great a benefit as
3 g/day, and therapeutic supplementation was found to be more efficacious than
regular supplementation [51-53]. Nevertheless, after 1975 only one paper has
reported a therapeutic trial administering 6 g/day [54]. Strangely enough, in
this double-blind, placebo-controlled trial patients receiving vitamin C could be
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identified by their clinical progress, which led to the breakdown of blindness in
the trial [54], Since 1975 several trials have examined the effect of a regular 1
g/day dose [48-51], which seems largely a waste of time and resources consider-
ing the data published before those trials.
According to the available evidence, there is no sound reason to research the
effects of regular vitamin C supplementation on the incidence of infections in
Western countries, except in carefully selected population groups. Regular sup-
plementation trials are recommended in populations with low vitamin C
intakes combined with a particular problem with infections. Such conditions
are common in the developing countries.
Therapeutic trials on various infections are encouraged, irrespective of the
nutritional background of the patients, although the greatest benefits may be
anticipated with patients initially having an unsatisfactory diet. Different doses
and different supplementation protocols should be compared in such trials. In
planning such therapeutic trials, the reports by physicians who have been using
vitamin C in their clinical practice may provide useful information on appro-
priate doses and on the possible ways of administering the vitamin.
Conclusions
In the first part of this century numerous reports were published, concluding
that vitamin C has effects on various infections. Szent-Györgyi himself believed
at the end of the 1930s that "vitamins, if properly understood and applied, will
help us reduce human suffering to an extent which the most fantastic mind
would fail to imagine [99]." In those days Szent-Györgyi was shocked by the
lack of biological insight and by the lack of interest in the basic problems on the
part of the leading clinicians [103].
The role of vitamin C in preventing and treating infections was not dis-
missed because of large-scale controlled trials showing that the vitamin is inef-
fective. There seem to be two particular reasons why the early reports were dis-
regarded. Antibiotics were introduced in the middle of this century. They have
specific effects on bacteria and are therefore much more rational drugs for
patients with specified infections than vitamin C. The second reason seems to
be the strong adherence to the notion that vitamin C is just for preventing
scurvy. Evidently it was unreasonable to consider that a substance participating
in collagen synthesis might have effects on infections. However, the biochem-
istry of vitamin C is complex and not at all limited to collagen metabolism.
Numerous reports have shown that vitamin C has effects on the immune system
[3-5]. Vitamin C is not a specific agent against any particular infection but pos-
sibly has moderate effects on general resistance to infections. Much more work
is needed to discover the practical importance of vitamin C in preventing and
treating infections.
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